FibroBiologics (FBLG) Total Liabilities (2022 - 2026)

FibroBiologics (FBLG) has reported Total Liabilities for 5 consecutive years, with $3.3 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Total Liabilities fell 74.76% year-over-year to $3.3 million; the trailing twelve-month figure through Jun 2026 stood at $3.3 million (down 74.76% YoY), and the FY2025 full-year result was $3.5 million, down 74.74% from the prior year.
• Total Liabilities slipped to $3.3 million in Q2 2026 per FBLG's latest filing, from $3.3 million in the prior quarter.
• Across five years, Total Liabilities topped out at $15.3 million in Q1 2024 and bottomed at -$11.4 million in Q2 2023.
• Historically, Total Liabilities has averaged $5.7 million across 5 years, with a median of $8.6 million in 2025.
• The sharpest annual moves came in 2024 and 2026: Total Liabilities jumped 2488.42% in 2024, then tumbled 74.76% in 2026.
• Over 5 years, Total Liabilities stood at $8.8 million in 2022, then increased by 19.82% to $10.6 million in 2023, then rose by 29.73% to $13.7 million in 2024, then plunged by 74.74% to $3.5 million in 2025, then retreated by 4.91% to $3.3 million in 2026.
• According to Business Quant data, Total Liabilities over the past three periods registered $3.3 million, $3.3 million, and $3.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.